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Background: Currently, no clearly superior management strategy exists for recurrent, platinum-resistant ovarian
cancer. We tested the efficacy and safety of gemcitabine combined with oxaliplatin (GEMOX) in a multicentre phase II
clinical trial.
Methods: Forty one patients with recurrent, platinum-resistant ovarian cancer were enrolled. Prior to study entry, all
the participants had received at least one platinum-based regimen. Gemcitabine was administered at 1000 mg/m2 as
protracted infusion (100 min) on day 1, and oxaliplatin at the dose of 100 mg/m2 on day 2 in a 2 hour infusion.
Cycles were repeated every two weeks.
Results: We observed an overall response rate of 37% [95% Confidence Interval (CI), 22.3–51.7]. Objective responses
plus disease stabilization (clinical benefit) occurred in 78% of patients. Median progression-free survival was 6.8 months
(95% CI, 5.8–7.8), and median overall survival was 16.5 months (95% CI, 12.2–20.8). Median time to self-reported
symptom relief, which was described by 22 out of 27 symptomatic patients (81.5%), was 4 weeks (range, 2–8). Grade 4
neutropenia and febrile neutropenia were observed in 2 (5%) and 1 (2.5%) patients, while grade 3 anemia was
encountered in 2 (5%) patients, respectively. The most common adverse effects of any grade were gastrointestinal
symptoms, fatigue and neutropenia. Nine patients (22%) experienced mild allergic reaction to oxaliplatin, with no
treatment discontinuation.
Conclusions: In our cohort of recurrent, platinum-resistant ovarian cancer patients, GEMOX showed encouraging
activity and manageable toxicity. Under circumstances requiring a rapid disease control, this combination regimen
may offer a particularly viable option, particularly in heavily pretreated patients.
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In Western countries, ovarian cancer represents the lead-
ing cause of death among women with gynaecological ma-
lignancies and the fifth most frequent cause of cancer
related death in women [1]. Front-line chemotherapy for
advanced epithelial ovarian cancer is currently based on a
combination of platinum-derived chemotherapeutic agents
(i.e. cisplatin or carboplatin) and paclitaxel. Despite the* Correspondence: pvici@ifo.it
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reproduction in any medium, provided the orhigh response rate and satisfactory median progression-
free survival (PFS), over 70% of patients experience disease
progression and require further treatments [2].
Re-treatment with a platinum compound in the plat-
inum “sensitive” subgroup, i.e. patients recurring after
12 months from the end of a platinum-based chemo-
therapy, yields response in up to 70% of cases. Con-
versely, in platinum “resistant” or “refractory” patients,
the administration of agents such as liposomal doxo-
rubicin, topotecan, gemcitabine, vinorelbine, docetaxel,
etoposide, ifosfamide, and oxaliplatin, is associated with
a response rate ranging from 10 to 33%, with a median. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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platinum-refractory or resistant recurrence have been in-
creasingly treated with more than one line of chemother-
apy. However, the actual benefits of currently available
treatment options in these patients are poorly documented,
particularly beyond the second-line [4,5].
Gemcitabine (GEM; 2,2-difluorodeoxycitidine), a syn-
thetic nucleoside analog of cytidine, inhibits S-phase of
cellular cycle. Several trials have confirmed its efficacy in
ovarian cancer patients, with response rates up to 22%
in platinum-resistant disease and a median response
duration ranging from 4 to 10 months. This drug is usu-
ally well tolerated, with non-cumulative myelotoxicity be-
ing the dose-limiting toxicity [3-5]. Oxaliplatin (OX) is a
diaminocyclohexane platinum analog with a partial lack
of cross-resistance with carboplatin or cisplatin [6,7]. In
recurrent ovarian cancer, OX administration was associ-
ated with a 16 to 29% response rate and a substantially
different toxicity pattern compared to “classic” platinum
compounds [8-11].
The GEMOX combination was first investigated by
Faivre et al., showing synergistic effects in human cell
lines [12]. A dose-finding combination trial proved feasi-
bility and activity in ovarian cancer patients and phase II
trials confirmed its efficacy in recurrent disease, with re-
sponses ranging from 9.5% to 37%, median PFS between
4.6 and 7.1 months, and an overall acceptable toxicity
[13-17]. The still limited number of studies reporting on
treatment outcomes in patients treated with GEMOX,
along with the limited evidence concerning the efficacy
of this combination in heavily pretreated patients, en-
courage further research. On this basis, we conducted a
multicentre, phase II clinical trial to evaluate efficacy
and safety of GEMOX in a cohort of ovarian cancer pa-
tients with recurrent, platinum-resistant disease.
Methods
Patients were eligible if aged 18 years and older and with
histologically or cytologically proven, advanced epithelial
ovarian cancer. Further requirements were having re-
ceived at least one previous front-line regimen including
paclitaxel combined with carboplatin or cisplatin. Prior
radical or debulking surgery, including peritonectomy
and Hiperthermic Intraperitoneal Chemotherapy (HIPEC),
were allowed. Patient eligibility was also dependent upon
the presence of at least one measurable and/or evaluable
target lesion documented by imaging, ECOG perform-
ance status ≤ 2, adequate bone marrow, cardiac, liver
and renal function (glomerular filtration rate according
to the Cockroft-Gault formula <60 ml min-1), absence
of symptomatic brain metastases, peripheral neurotox-
icity ≥ grade 1 according to the National Cancer Institute-
Common Toxicity Criteria version 4.0 (NCI-CTC v. 4.0),
no previous or concomitant serious diseases, includingother malignancies except cutaneous basal cell carcinoma
and cervical intraepithelial neoplasia. No previous treat-
ment with GEM or OX or any concomitant experimental
treatment were allowed.
On study entry, patients were categorized into subsets
on the basis of the platinum free interval (PFI), defined
as the interval from the last date of platinum dose until
progressive disease was documented. Disease was con-
sidered as follows: a) Refractory, if progression occurred
while on the last line of platinum-based therapy or
within 4 weeks from the last platinum dose; b) Resistant,
if the PFI was less than 6 months; c) Partially platinum-
sensitive, if the PFI was between 6 and 12 months and
d) Fully platinum-sensitive, if the PFI was longer than
12 months [18]. To our study purposes, we considered
eligible all patients but those from the subgroup d.
Disease evaluation included physical examination, weekly
complete haemato-biochemical assessment and measure-
ment of serum Ca 125 at every cycle, as well as radiologic
evaluation every 3 cycles. All patients received GEM,
1000 mg/m2 as protracted infusion (100 min) on day 1,
and OX, at the dose of 100 mg/m2 administered on day 2
in a 2 hour infusion. Cycles were repeated every two
weeks, without prophylactic hematopoietic growth factor
administration. Standard antiemetic prophylaxis was ad-
ministered to all the patients.
Eligible patients who received at least one dose of
gemcitabine or oxaliplatin were included in both the effi-
cacy and safety analysis. Efficacy was analyzed for the
intention to treat population (ITT), using the enrolled
patients as denominator. Tumor response was evaluated
according to the response evaluation criteria for solid
tumours (RECIST). PFS and overall survival (OS) were
calculated from the date of first chemotherapy cycle to
the date of disease progression, treatment refusal, death
for any cause or lost follow-up evaluation, respectively.
Toxicity was graded according to the NCI-CTC v. 4.0. A
25% drug dose-reduction was planned for grade (G) 4 neu-
tropenia or febrile neutropenia, G3-4 thrombocytopenia or
other G3-4 extra-hematological toxicities, and G2-3 neuro-
toxicity; in case of more severe neurotoxicity, treatment
discontinuation was planned. G-CSF administration was
allowed in case of G4 neutropenia, along with its
prophylactic use in subsequent cycles. Chemotherapy
was usually administered on an outpatient basis for
a maximum of 12 cycles. Treatment was discontinued in
case of disease progression, unacceptable toxicity, treat-
ment delay longer than 2 weeks or patient refusal. The
study protocol was approved by the Ethic Committee
of the Regina Elena National Cancer Institute, the coord-
inating centre. A written informed consent was obtained
from all the enrolled patients prior to any trial pro-
cedure. The project was carried out according to the
Helsinki Declaration.
Table 1 Main patient characteristics
Characteristic No. of patients %









Serous adenocarcinoma 10 24.5
Adenocarcinoma 7 17
Papillary serous 6 15
Clear cell adenocarcinoma 2 5
Endometrioid 3 7
Mucinous adenocarcinoma 3 7
Poorly differentiated 10 24.5
Stage at diagnosis
I,II 2 5
III (A, B, C) 33 (10, 12, 11) 80
IV 6 15








Abbreviations: ECOG PS, Eastern Cooperative Oncoloy Group Performance Status.
Table 2 Objective response in 41 patients
Responses No. of patients %
Complete response 2 5
Partial response 13 32
Stable disease 17 41
Progressive disease 9 22
Clinical Benefit 32 78
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Primary objectives of the study were the evaluation of
response rate (RR) and PFS, while safety and OS were
secondary aims. The optimal Simon's two-stage phase II
design was used to determine the sample size [19]. An
interim analysis was carried out when the first 13 assess-
able patients were recruited. If more than 3 responses
were observed, 30 additional patients had to be recruited;
otherwise, the study had to be terminated. If more than
12 responses were observed in the 43 patients, the regi-
men was considered sufficiently active with a significance
level of 5% and power of 80% to be submitted for further
evaluation. The enrolment of 41 patients ensured a suffi-
cient number of events required for statistical analysis.
PFS and OS were analyzed according to the Kaplan-
Meier method. Follow-up was updated to 30 April 2013.
Results
Patients characteristics
Overall, 41 ovarian patients with recurrent, platinum-
resistant disease were enrolled between March 2010 and
December 2012. Main patient characteristics are listed
in Table 1. Median age was 60 years (range, 32–75). Ser-
ous adenocarcinomas and poorly differentiated tumours
were the most common histological subtypes (24.5%,
equally represented), while stage III FIGO at the diagno-
sis was largely predominant (80%). By preset inclusion
criteria, all the patients had received at least one previous
platinum-based regimen and were platinum-resistant on
study entry. Twenty three patients (56%) were defined
platinum-refractory or resistant, while for 18 women
(44%) the PFI fell in a 6 to 12 month interval (partially
platinum-sensitive). Thirty eight patients (93%) had been
previously treated with at least two lines of chemother-
apy. Eighteen women (44%) had received no less than
two previous platinum-based regimens. All the patients
had received paclitaxel, one also docetaxel. Thirty seven
patients (90%) had also received liposomal doxorubicin.
Efficacy
A median number of 8 cycles of GEMOX were adminis-
tered (range, 2 to 12). One patient refused further treat-
ment after the 2nd chemotherapy cycle. All patients
were fully evaluable for response and toxicity.
Based on ITT analysis, 2 (5%) complete responses
(CR) and 13 (32%) partial responses (PR) were observed
in 41 enrolled patients, for an overall response rate of
37% (95% CI, 22.3 to-51.7%.). Stable disease was ob-
served in 17 patients (41%). A clinical benefit (objective
responses + stable disease) was documented in 32 patients
(78%) (95% CI, 65–91) (Table 2). Among patients whose
disease was originally partially platinum-sensitive, response
rate was 50%, while in platinum-resistant or refractory pa-
tients response rate was 26%. The PFS was 6.8 months(95% CI, 5.8–7.8) (Figure 1), with no significant difference
between initially platinum-sensitive and platinum-resistant
patients (7.0 and 6.7 months, respectively). After a median
follow-up of 14.5 months (range, 2 to 30), 69.2% and
10.1% patients were alive at 1 and 2 years, respectively; the
median OS for the whole cohort was 16.5 months (95% CI,
12.2–20.8) (Figure 2). The median time to self-reported
Figure 1 Progression free survival (PFS).
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atic patients (81.5%), was 4 weeks (range, 2–8 weeks); even
if symptom improvement translated into objective re-
sponse in only 8 patients, some degree of amelioration in
quality of life was reported by the vast majority of symp-
tomatic patients.
Toxicity
The dose-limiting toxicity was hematological, with G4 neu-
tropenia and febrile neutropenia observed in 2 (5%) pa-
tients and 1 (2.5%) patient, respectively, requiring G-CSF
administration. G1-2 thrombocytopenia were observed in
4 (10%) and 6 (15%) patients, respectively; no cases of G3
or G4 thrombocytopenia were reported. Grade 3 anemia
was encountered in 2 (5%) patients, whereas G1-2 anemia
was commonly observed (34% and 29%, respectively).
Treatment delays because of hematological or extra-Figure 2 Overall survival (OS).hematological toxicities were needed in 4 patients (9.7%).
Dose-reductions were required in 3 (7.3%) patients because
of G2 neurotoxicity. No cases of G3 or more severe neuro-
toxicity were observed, while G1 neurotoxicity occurred in
2 patients (5%). Nine patients (22%) experienced mild aller-
gic reaction to OX, usually after the 6th cycle, but no dis-
continuation of treatment occurred. Nausea and vomiting
were mainly G1-2, being G3 in only 2 patients. All patients
developed alopecia. No toxic deaths were observed. Main
toxicities are reported in Table 3.
Discussion
Recurrent, platinum-resistant ovarian cancer represents a
major challenge to modern oncology. GEMOX is a com-
bination regimen with proven activity and overall tolerable
toxicity both in pretreated [14-17,20] and first-line treated
ovarian patients [21]. However, the related scientific pano-
rama is still remarkably limited by the restricted number of
targeted studies and paucity of data on heavily pre-treated
patients. In this context, our multicentre, phase II trial pro-
vides evidence concerning GEMOX efficacy and safety in a
cohort of 41 patients with recurrent, platinum-resistant
ovarian cancer. It is noteworthy that among patients in-
cluded, all but three had received at least two previous
lines of chemotherapy.
In our cohort, the GEMOX regimen yielded an overall
response rate of 37% (95% CI, 22.3 to-51.7%). In addition,
induced objective response plus disease stabilization
(clinical benefit) occurred in 78% of patients and relief
from disease-related symptoms was reported by the major-
ity of symptomatic patients (81.5%), even though this did
seldom translate into objective response. Overall, the regi-
men was well tolerated, with the major reactions being
hematological. The choice of a biweekly schedule insteadTable 3 Main toxicity in 41 patients
Toxicity Grade 1% Grade 2% Grade 3% Grade 4%
Hematologic
Leukopenia 12 5 5 -
Neutropeniaa 27 10 10 5
Thrombocytopenia 10 15 - -
Anemia 34 29 5 -
Nonhemathologic
Nausea/Vomiting 24 15 5 -
Diarrhea 15 15 5 -
Fatigue 29 10 - -
Neurotoxicity 5 7 - -
Hypertransaminases 12 10 2.5 -
Conjunctivitis 5 2.5 - -
Hypersensivity 7 15 - -
aFebrile neutropenia in 1 patient (2.5%).
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2–3 peripheral neurotoxicity, while the 3-weekly adminis-
tration usually gives rise to more severe myelotoxicity. In
our study, no significant increase of peripheral neurotox-
icity occurred. Indeed, no patients experienced grade 3
neurotoxicity, being neurotoxic effects manageable in the
majority of patients.
Results from our trial fairly compare with those from
most of the previous reports [14-17,20]. Conversely, due
to modest response and relatively high toxicity, Harnett
and colleagues defined the GEMOX regimen “unsatisfac-
tory for further study”, but, in this trial, the inclusion of
eighteen women (20%) diagnosed with primary periton-
eal and Fallopian tube carcinomas, rare tumours com-
monly associated with the hereditary breast and ovarian
cancer syndrome, might have added heterogeneity to the
study population and diminished comparability to other
studies. Moreover, dissimilarities in the administration
schedule might help explain discrepancies in safety out-
comes [22].
In the setting of recurrent, platinum-resistant disease,
GEM has been variously combined with other drugs.
Several trials assessed efficacy and tolerability of GEM/
paclitaxel combination, reporting responses in up to 40%
of paclitaxel-naïve patients [23]. The combination of
GEM/topotecan was tested in phase I-II trials, with some
encouraging results even in resistant disease [24], while
GEM/docetaxel combination offered response rate of 25%
in platinum resistant patients [25]. The GEM/liposomal
doxorubicin regimen was used in mostly platinum resistant
ovarian cancer patients, yielding response rates ranging
from 22 to 42.8%, and a median time to progression and
OS from 2.7 to 7.7, and 8.4 to 17 months, respectively
[26-31]. Oral etoposide, vinorelbine, irinotecan provide ex-
amples of further drugs variously combined with GEM in
recurrent, platinum resistant ovarian cancer, with response
rates between 10 and 30% [32]. Some authors tested a
triple combination including GEM as salvage treatment in
resistant disease, without significant benefit over doublets
or single-agent [33].
In advanced ovarian cancer, OX was less extensively eval-
uated compared to GEM. In pretreated patients, OX com-
bination with topotecan and liposomal doxorubicin yielded
some encouraging results, showing 29% and 31.5% of re-
sponses, with a median PFS and OS of 5.5 to 7.3 and 10 to
15.5 months in mostly, though not exclusively, platinum
resistant patients [34-37]. OX-based combinations with
paclitaxel or fluorouracil appear promising in platinum
resistant disease [38-40]. In this setting, further doublet
combinations including docetaxel/irinotecan, carboplatin/
irinotecan, and topotecan/etoposide showed results com-
parable by magnitudo to those of single-agents [41-43].
The potential advantage of combination regimens over
single agent therapy in patients with recurrent, platinumresistant disease is still under debate. Indeed, results from
several randomized clinical trials consistently favour the
use of single agents. However, under circumstances re-
quiring a rapid disease control, particularly in heavily
pretreated patients, and with large amount of disease,
combination schemes may represent a valid therapeutic
option targeted at symptom palliation and eventual object-
ive response, with an acceptable toxicity [44-46]. Based on
our results and consistently with previous reports, the
GEMOX regimen administered according to the schedule
described in the present trial showed encouraging results,
given the induction of response or disease stabilization in
78% of cases and relief from symptoms in a even higher
percentage of symptomatic patients (about 81%). A com-
parison of the disease control duration and patient quality
of life achieved with GEMOX or single agents will be
needed in future studies.
Several molecularly targeted agents have been tested in
ovarian cancer, now entering clinical trials. Recently, the
Aurelia trial has shown advantages in PFS in the experi-
mental arms, including standard chemotherapy (topotecan,
liposomal doxorubicin, or paclitaxel), in combination with
bevacizumab, over chemotherapy alone in the setting of
platinum resistant patients [47].
A preliminary experience of weekly administration of
GEMOX and bevacizumab in recurrent refractory ovarian
cancer showed an overall response rate of 32%, with a very
high rate of clinical benefit (79%), and a median PFS of
4.5 months, with mild toxicities [48]. Further trials of
targeted agents in combination with chemotherapy are on-
going, aiming at the identification of predictive biomarkers
and deeper knowledge of molecular biology of ovarian can-
cer [49]. In the meantime, the choice of “standard” chemo-
therapy with drugs exhibiting no cross-resistance with
platinum, paclitaxel and liposomal anthracyclines, remains
a reasonable option in the setting of pretreated and resist-
ant disease. However, at present, no clearly superior man-
agement strategy exists for recurrent, platinum resistant/
refractory ovarian cancer, particularly in heavily pretreated
patients, and beyond the third line, response rates signifi-
cantly decline, with no reported advantages in OS [3]. In
this setting, single-agent therapy is usually recommended,
and combination regimens have frequently been shown to
increase toxicity without benefit in PFS or OS. Still, given
the particularly poor prognosis of pretreated and resistant
ovarian cancer patients [50], optimization of quality of life
at the lowest toxicity might be a more appropriate out-
come compared with survival. In such a context, the
GEMOX combination may offer a viable option to patients
with recurrent, platinum resistant disease.
Conclusions
In a cohort of 41 recurrent platinum resistant epithelial
ovarian cancer patients, the GEMOX regimen showed
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and manageable toxicity. Moreover, independently on its
translation into objective response, self-reported symp-
tom relief was described by the majority of symptomatic
patients and occurred in an acceptable time window.
On this basis, GEMOX may offer a particularly viable
option in this patient population, particularly in heavily
pretreated women.
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